Blackstone Will Pay Up to $1.5 Billion of Development Costs for Pfizer's Monthly GLP-1 Drug Berobenatide Through 2028
Funds managed by Blackstone Life Sciences will cover up to $1.5 billion of development costs through 2028 for berobenatide (PF'3944), Pfizer's investigational once-monthly GLP-1 receptor agonist peptide, in exchange for milestone payments tied to U.S. approval of monthly berobenatide for chronic weight management and to sales targets, Pfizer said on November 11. Blackstone gets no rights or ownership in the drug, and Pfizer keeps full control of the program, which includes 10 ongoing and planned Phase 3 trials covering weight management, knee osteoarthritis, and obstructive sleep apnea.